The angiogenic effect of dracorhodin perchlorate on human umbilical vein endothelial cells and its potential mechanism of action

Li,Feng; Jiang,Tao; Liu,Wei; Hu,Quan; Yin,Huinan

doi:10.3892/mmr.2016.5442

The angiogenic effect of dracorhodin perchlorate on human umbilical vein endothelial cells and its potential mechanism of action

Authors:
- Feng Li
- Tao Jiang
- Wei Liu
- Quan Hu
- Huinan Yin
View Affiliations

Affiliations: Department of Burns and Plastic Surgery, The First Affiliated Hospital of the General Hospital of People's Liberation Army of China, Beijing 100048, P.R. China, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, P.R. China
Published online on: June 23, 2016 https://doi.org/10.3892/mmr.2016.5442
Pages: 1667-1672

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hyperglycemia is the key clinical feature of diabetes, and may induce refractory wound lesions and impaired angiogenesis. Dracorhodin perchlorate (Dra) is the major ingredient of dragon's blood and it has been used as a medicine to treat chronic wounds, such as diabetic foot, since ancient times in many cultures. The current study aimed to investigate the effect of Dra on human umbilical vein endothelial cells (HUVECs) under high‑glucose (HG) stimulation and its potential mechanism. Dra was observed to increase the multiplication capacity of HUVECs both under low glucose (LG) and HG concentrations. Additionally, migration and tube formation in HUVECs was facilitated by Dra. The expression levels of Ras, mitogen‑activated protein kinase (MAPK) and vascular endothelial growth factor, which are key components of the Ras/MAPK pathway, were upregulated following Dra treatment. The present study is the first report, to the best of our knowledge, of the effects of Dra on wound healing, and the association with the Ras/MAPK signaling pathway.

View Figures

View References

1	Bedell AJ: Retinal Vessel Proliferation in Diabetes. Trans Am Ophthalmol Soc. 43:271–276. 1945.PubMed/NCBI
2	Cholst MR, Levitt LM and Handelsman MB: Small vessel dysfunction in patients with diabetes mellitus. II. Retinal vessel response in diabetics following priscoline. Am J Med Sci. 224:39–41. 1952. View Article : Google Scholar : PubMed/NCBI
3	Colwell JA and Lopes-Virella MF: A review of the development of large-vessel disease in diabetes mellitus. Am J Med. 85(5A): 113–118. 1988. View Article : Google Scholar : PubMed/NCBI
4	Pedersen J and Olsen S: Small-vessel disease of the lower extremity in diabetes mellitus. On the pathogenesis of the foot-lesions in diabetics. Acta Med Scand. 171:551–559. 1962. View Article : Google Scholar : PubMed/NCBI
5	Kavitha KV, Tiwari S, Purandare VB, Khedkar S, Bhosale SS and Unnikrishnan AG: Choice of wound care in diabetic foot ulcer: A practical approach. World J Diabetes. 5:546–556. 2014. View Article : Google Scholar : PubMed/NCBI
6	Falanga V: Wound healing and its impairment in the diabetic foot. Lancet. 366:1736–1743. 2005. View Article : Google Scholar : PubMed/NCBI
7	Walshe TE and D'Amore PA: The role of hypoxia in vascular injury and repair. Annu Rev Pathol. 3:615–643. 2008. View Article : Google Scholar
8	Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ and Gilbert RE: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 48:2229–2239. 1999. View Article : Google Scholar : PubMed/NCBI
9	Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD and Adamis AP: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 42:2408–2413. 2001.PubMed/NCBI
10	Advani A, Connelly KA, Advani SL, Thai K, Zhang Y, Kelly DJ and Gilbert RE: Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes. BioMed Res Int. 2013:2014752013. View Article : Google Scholar : PubMed/NCBI
11	Chang Y, Chang TC, Lee JJ, Chang NC, Huang YK, Choy CS and Jayakumar T: Sanguis draconis, a dragon's blood resin, attenuates high glucose-induced oxidative stress and endothelial dysfunction in human umbilical vein endothelial cells. Scientific-World Journal. 2014:4232592014. View Article : Google Scholar : PubMed/NCBI
12	Liu H, Lin S, Xiao D, Zheng X, Gu Y and Guo S: Evaluation of the Wound Healing Potential of Resina Draconis (Dracaena cochinchinensis) in Animal Models. Evid Based Complement Alternat Med. 2013:7098652013. View Article : Google Scholar : PubMed/NCBI
13	Zhang P, Li J, Tang X, Zhang J, Liang J and Zeng G: Dracorhodin perchlorate induces apoptosis in primary fibroblasts from human skin hypertrophic scars via participation of caspase-3. Eur J Pharmacol. 728:82–92. 2014. View Article : Google Scholar : PubMed/NCBI
14	Yu JH, Zheng GB, Liu CY, Zhang LY, Gao HM, Zhang YH, Dai CY, Huang L, Meng XY, Zhang WY and Yu XF: Dracorhodin perchlorate induced human breast cancer MCF-7 apoptosis through mitochondrial pathways. Int J Med Sci. 10:1149–1156. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hu Q, Sun E, Xu FJ, Zhang ZH and Jia XB: Simultaneous content determination of notoginsenoside R1, ginsenoside Rg1, Re, Rb1 and dracorhodin in ZJHX rubber paste by double wavelength HPLC. Zhongguo Zhong Yao Za Zhi. 38:2793–2797. 2013.In Chinese.
16	Rasul A, Ding C, Li X, Khan M, Yi F, Ali M and Ma T: Dracorhodin perchlorate inhibits PI3K/Akt and NF-κB activation, upregulates the expression of p53, and enhances apoptosis. Apoptosis. 17:1104–1119. 2012. View Article : Google Scholar : PubMed/NCBI
17	He Y, Ju W, Hao H, Liu Q, Lv L and Zeng F: Dracorhodin perchlorate suppresses proliferation and induces apoptosis in human prostate cancer cell line PC-3. J Huazhong Univ Sci Technolog Med Sci. 31:215–219. 2011. View Article : Google Scholar : PubMed/NCBI
18	Xia MY, Wang MW, Cui Z, Tashiro SI, Onodera S, Minami M and Ikejima T: Dracorhodin perchlorate induces apoptosis in HL-60 cells. J Asian Nat Prod Res. 8:335–343. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zhang P, Li J, Tang X, Zhang J, Liang J and Zeng G: Dracorhodin perchlorate induces apoptosis in primary fibroblasts from human skin hypertrophic scars via participation of caspase-3. Eur J Pharmacol. 728:82–92. 2014. View Article : Google Scholar : PubMed/NCBI
20	Roy DC, Mooney NA, Raeman CH, Dalecki D and Hocking DC: Fibronectin matrix mimetics promote full-thickness wound repair in diabetic mice. Tissue Eng Part A. 19:2517–2526. 2013. View Article : Google Scholar : PubMed/NCBI
21	Liu S, Li Z and Qian G: Quantitative determination of dracorhodin in Daemonorops draco B1. and traditional Chinese medicines containing Daemonorops draco B1. by HPLC. Hua Xi Yi Ke Da Xue Xue Bao. 28:450–453. 1997.In Chinese.
22	Xia M, Wang D, Wang M, Tashiro S, Onodera S, Minami M and Ikejima T: Dracorhodin perchlorate induces apoptosis via activation of caspases and generation of reactive oxygen species. J Pharmacol Sci. 95:273–283. 2004. View Article : Google Scholar : PubMed/NCBI
23	Corral CJ, Siddiqui A, Wu L, Farrell CL, Lyons D and Mustoe TA: Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing. Arch Surg. 134:200–205. 1999. View Article : Google Scholar : PubMed/NCBI
24	Kolch W: Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 351:289–305. 2000. View Article : Google Scholar : PubMed/NCBI